Glycosylation in health and disease

C Reily, TJ Stewart, MB Renfrow, J Novak - Nature Reviews Nephrology, 2019 - nature.com
The glycome describes the complete repertoire of glycoconjugates composed of
carbohydrate chains, or glycans, that are covalently linked to lipid or protein molecules …

[HTML][HTML] The diagnosis and treatment of Sjögren's syndrome

AL Stefanski, C Tomiak, U Pleyer… - Deutsches Ärzteblatt …, 2017 - ncbi.nlm.nih.gov
Background Sjögren's syndrome is one of the more common inflammatory rheumatological
diseases, with a prevalence of at least 0.4% in Germany. Methods This review is based on …

[HTML][HTML] Aberrant protein glycosylation: Implications on diagnosis and Immunotherapy

R Bangarh, C Khatana, S Kaur, A Sharma… - Biotechnology …, 2023 - Elsevier
Glycosylation-mediated post-translational modification is critical for regulating many
fundamental processes like cell division, differentiation, immune response, and cell-to-cell …

Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls

H Rincon-Arevalo, A Wiedemann, AL Stefanski… - Frontiers in …, 2021 - frontiersin.org
Circulating CD11c+ B cells are a key phenomenon in certain types of autoimmunity but have
also been described in the context of regular immune responses (ie, infections, vaccination) …

Altered increase in STAT1 expression and phosphorylation in severe COVID‐19

H Rincon‐Arevalo, A Aue, J Ritter… - European journal of …, 2022 - Wiley Online Library
The interferon pathway, a key antiviral defense mechanism, is being considered as a
therapeutic target in COVID‐19. Both, substitution of interferon and JAK/STAT inhibition to …

Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing …

J Rodríguez-Carrio, A Burska, PG Conaghan… - RMD open, 2023 - rmdopen.bmj.com
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …

Moving towards a molecular taxonomy of autoimmune rheumatic diseases

G Barturen, L Beretta, R Cervera… - Nature Reviews …, 2018 - nature.com
Autoimmune rheumatic diseases pose many problems that have, in general, already been
solved in the field of cancer. The heterogeneity of each disease, the clinical similarities and …

Treatment of Sjögren's syndrome: current therapy and future directions

RI Fox, CM Fox, JE Gottenberg, T Dörner - Rheumatology, 2021 - academic.oup.com
SS is usually described as having severe fatigue, dryness, diffuse pain, glandular swelling,
and various extraglandular (systemic) manifestations. Clinical trials have generally failed …

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

A Burska, J Rodríguez-Carrio, R Biesen, WA Dik… - RMD open, 2023 - rmdopen.bmj.com
Objectives To systematically review the literature for assay methods that aim to evaluate type
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …

[PDF][PDF] Type I interferon signature in Sjögren's syndrome: Pathophysiological and clinical implications

N Marketos, I Cinoku, A Rapti… - Clin Exp …, 2019 - clinexprheumatol.org
Type I interferons (IFN) have long been recognised as mediators of innate immune defense
mechanisms against viral threats. Robust evidence over the last 15 years revealed their …